Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

19+ things to know about UNC Spring Commencement speaker Mia Hamm
Former North Carolina women’s soccer star Mia Hamm (class of 1994) is stepping onto a different field in Chapel Hill on May 10. She’ll join...
Wed May 7, 2025

National drone racing championship comes to Carolina
Carolina doesn’t have a drone team of its own yet, but Joseph Sharp - the fabrication education specialist with the Lampe Joint Department of Biomedical...
Wed May 7, 2025

Suki Lin: UNC’s hidden gem
UNC is filled with notable figures but there is one bright star on UNC’s YikYak: the corgi, Suki Lin. Suki first became known to the...
Sun May 4, 2025

Jim Lampley wasn't supposed to fall in love with boxing. Instead, he became its voice
Jim Lampley has been the voice of boxing for a generation, which is remarkable because the assignment was only supposed to last one fight. In...
Fri May 2, 2025